Display options
Cite
Alavian SM, Haghbin H. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review. Hepat Mon. 2016;16(3):e35106doi: 10.5812/hepatmon.35106.
Alavian, S. M., & Haghbin, H. (2016). Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review. Hepatitis monthly, 16(3), e35106. https://doi.org/10.5812/hepatmon.35106
Alavian, Seyed Moayed, and Haghbin, Hossein. "Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review." Hepatitis monthly vol. 16,3 (2016): e35106. doi: https://doi.org/10.5812/hepatmon.35106
Alavian SM, Haghbin H. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review. Hepat Mon. 2016 Mar 06;16(3):e35106. doi: 10.5812/hepatmon.35106. eCollection 2016 Mar. PMID: 27226803; PMCID: PMC4875504.
Copy Download .nbib Format: NLM
Share it on

Hepat Mon. 2016 Mar 06;16(3):e35106. doi: 10.5812/hepatmon.35106. eCollection 2016 Mar.

Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review.

Hepatitis monthly

Seyed Moayed Alavian, Hossein Haghbin

Affiliations

  1. Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran.

PMID: 27226803 PMCID: PMC4875504 DOI: 10.5812/hepatmon.35106

Abstract

CONTEXT: Hepatocellular carcinoma (HCC) is the second most common cancer-related death worldwide. Although many factors including dietary aflatoxin B1 (AFB1) and alcoholic and non-alcoholic fatty liver diseases can lead to HCC, globally most HCC cases are due to hepatitis B virus (HBV) and hepatitis C virus (HCV). Considering the importance of these viral factors in most HCC cases and relative lack of literature from eastern Mediterranean region office of world health organization (EMRO) countries and the Middle East, we decided to perform this systematic review to find distribution of viral etiology of HCC in these regions.

EVIDENCE ACQUISITION: In this systemic review, we included all studies from 1 January 1989 to 1 September 2015 with at least 20 samples that measured HBV surface antigen (HBsAg) and antibodies to HCV (anti-HCV). The authors searched MEDLINE, Embase, Popline, Web of Science and WHO indexed databases. We searched the following MeSH terms; hepatocellular carcinoma, hepatitis B virus and hepatitis C virus or hepacvirus. Only studies using second- and third-generation HCV assays were included. Only articles studying HCC patients from EMRO countries and the Middle East were analyzed. Duplicate results that reported the same cases more than once were found and omitted. Studies in English and Farsi were reviewed. If the study was eligible, we recorded the following data; the first author, publication year and journal, study population and number and percentage of patients with different serologic statuses.

RESULTS: We found 44 studies from 12 countries in EMRO and the Middle East. HCC cases from Iran, Lebanon, Turkey and Yemen were mainly due to HBV, while those of North African nations (Egypt, Tunisia, Morocco, Algeria and Somalia) in addition to Saudi Arabia and Pakistan were mostly HCV related. Sudan showed a high seronegativity and HBV infection in its HCC cases. Unfortunately, some countries from EMRO and the Middle East did not have eligible studies.

CONCLUSIONS: HBV and HCV are important culprits of HCC in EMRO countries and the Middle East and different nations need different strategies to tackle them accordingly. Countries with high rates of HBV such as Turkey should continue their HBV vaccination and also increase sanitation. Nations with high HCV rates such as Egypt should maintain their blood product monitoring in addition to increased sanitation, especially regarding injection drug users (IDU).

Keywords: Carcinoma; Hepatitis B Virus; Hepatitis C Virus; Hepatocellular; Review

References

  1. Hepat Mon. 2014 Jul 01;14(7):e16665 - PubMed
  2. Int J Cancer. 2006 Oct 15;119(8):1946-52 - PubMed
  3. Microbiol Mol Biol Rev. 2000 Mar;64(1):51-68 - PubMed
  4. BMC Infect Dis. 2014 Jan 07;14:7 - PubMed
  5. J Pak Med Assoc. 1998 Jul;48(7):197-201 - PubMed
  6. Eur J Gastroenterol Hepatol. 2013 Feb;25(2):166-79 - PubMed
  7. Epidemiol Infect. 1996 Oct;117(2):327-32 - PubMed
  8. Gastroenterology. 2012 Oct;143(4):974-85.e14 - PubMed
  9. East Mediterr Health J. 2012 Jul;18(7):693-9 - PubMed
  10. Saudi Med J. 2005 Jun;26(6):974-7 - PubMed
  11. World J Gastroenterol. 2009 Oct 28;15(40):5080-5 - PubMed
  12. J Pak Med Assoc. 2012 Jan;62(1):33-6 - PubMed
  13. J Coll Physicians Surg Pak. 2010 Aug;20(8):510-3 - PubMed
  14. BMC Res Notes. 2013 Apr 08;6:137 - PubMed
  15. Int J Cancer. 2006 Jun 15;118(12):3030-44 - PubMed
  16. BMC Med. 2014 Sep 18;12 :145 - PubMed
  17. Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2362-8 - PubMed
  18. J Gastroenterol Hepatol. 2004 Jun;19(6):665-9 - PubMed
  19. Turk Patoloji Derg. 2011;27(3):221-9 - PubMed
  20. Gut. 2001 Jul;49 Suppl 1:I1-21 - PubMed
  21. Saudi Med J. 2005 Apr;26(4):601-6 - PubMed
  22. World J Gastroenterol. 2005 Sep 7;11(33):5193-8 - PubMed
  23. Int J Hyg Environ Health. 2005;208(5):329-39 - PubMed
  24. Turk J Gastroenterol. 2003 Jun;14(2):85-90 - PubMed
  25. World J Gastroenterol. 2006 Jun 14;12(22):3575-80 - PubMed
  26. Scand J Infect Dis. 1993;25(5):559-64 - PubMed
  27. Trop Doct. 2001 Oct;31(4):224-5 - PubMed
  28. World J Hepatol. 2011 Jan 27;3(1):24-30 - PubMed
  29. J Pak Med Assoc. 2008 Nov;58(11):602-7 - PubMed
  30. J Viral Hepat. 2015 Dec;22 Suppl 4:42-65 - PubMed
  31. Liver Int. 2013 Nov;33(10):1601-6 - PubMed
  32. Clin Liver Dis. 2011 May;15(2):223-43, vii-x - PubMed
  33. J Ayub Med Coll Abbottabad. 2003 Oct-Dec;15(4):1-4 - PubMed
  34. Dig Dis Sci. 2010 Dec;55(12):3568-75 - PubMed
  35. J Viral Hepat. 2011 Jul;18(7):e399-407 - PubMed
  36. Carcinogenesis. 2013 Aug;34(8):1800-5 - PubMed
  37. J Egypt Public Health Assoc. 1993;68(1-2):1-9 - PubMed
  38. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  39. Jpn J Clin Oncol. 2008 Oct;38(10):683-8 - PubMed
  40. Asian Pac J Cancer Prev. 2008 Apr-Jun;9(2):295-8 - PubMed
  41. Asian Pac J Cancer Prev. 2012;13(6):2985-90 - PubMed
  42. Acta Virol. 2012;56(3):235-40 - PubMed
  43. J Hepatol. 2006 Oct;45(4):529-38 - PubMed
  44. J Viral Hepat. 2015 Dec;22 Suppl 4:21-41 - PubMed
  45. Ann Intern Med. 2009 Aug 18;151(4):264-9, W64 - PubMed
  46. J Med Virol. 2009 Jul;81(7):1189-97 - PubMed
  47. J Clin Gastroenterol. 2001 Aug;33(2):123-6 - PubMed
  48. J Med Virol. 2013 Sep;85(9):1518-22 - PubMed
  49. Asian Pac J Cancer Prev. 2012;13(8):3663-7 - PubMed
  50. Trop Doct. 1997 Jan;27(1):45-6 - PubMed
  51. Lancet. 1992 Apr 11;339(8798):928 - PubMed
  52. Mayo Clin Proc. 2012 Jan;87(1):17-24 - PubMed
  53. Br J Cancer. 2012 Jun 26;107(1):195-200 - PubMed
  54. Dig Dis Sci. 2001 May;46(5):1022-8 - PubMed
  55. Tunis Med. 2012 Jun;90(6):468-72 - PubMed
  56. Int J Hyg Environ Health. 2005;208(4):263-70 - PubMed
  57. J Hepatol. 2014 Nov;61(1 Suppl):S45-57 - PubMed
  58. Hepatogastroenterology. 2007 Jan-Feb;54(73):157-62 - PubMed
  59. Trans R Soc Trop Med Hyg. 2001 Sep-Oct;95(5):487-91 - PubMed
  60. J Gastrointest Cancer. 2011 Dec;42(4):228-35 - PubMed
  61. Dis Markers. 1997 Nov;13(3):177-82 - PubMed
  62. Eur J Epidemiol. 2010 Sep;25(9):603-5 - PubMed

Publication Types